Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
PMDA to Raise Its Service Fees, Up 28% for New Drug Reviews; MHLW Invites Public Opinions
The Ministry of Health, Labor and Welfare (MHLW) started inviting public opinions on January 11 on a draft governmental ordinance that proposes to raise the application review fees of Pharmaceuticals and Medical Devices Agency (PMDA). The draft ordinance proposes a…
To read the full story
Related Article
- Japan Cabinet OKs PMDA Review Fee Rise from April 1
March 18, 2019
- PMDA Eyeing Staffer Increase of Around 150 over Next 5 Years, Official Suggests
January 29, 2019
- PMDA to Specify Target Overall Review Period for Regenerative Medicine Products: FY2019-2023 Plan
January 17, 2019
- PMDA to Raise Fees and Expand Workforce to Boost Review and Safety Measures, GMP Inspection
January 15, 2019
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…